Clinical Trial: NCT05508867
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-09-01 |
Study Overview
Brief Summary
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.
Official Title
Conditions
Intervention / Treatment
- Biological: favezelimab/pembrolizumab
- Drug: bendamustine
- Drug: gemcitabine
Other Study ID Numbers
- 4280A-008
- MK-4280A-008
- 2023-503615-14-00
- U1111-1287-5864
- 2022-000371-39
- 2023
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-09-01 |
Study Overview
Brief Summary
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.
Official Title
Conditions
Intervention / Treatment
- Biological: favezelimab/pembrolizumab
- Drug: bendamustine
- Drug: gemcitabine
Other Study ID Numbers
- 4280A-008
- MK-4280A-008
- 2023-503615-14-00
- U1111-1287-5864
- 2022-000371-39
- 2023